comparability exercise including physicochemical characterisation, biological activity, pharmacokinetics, safety and drug effect (2, 5) . This demonstration requires the use of the most sensitive studies and variables for each comparison. In terms of clinical data, it is widely accepted that pharmacodynamics/pharmacokinetics evaluations using biomarkers are much more sensitive approaches to detect differences between a BS and its RP that any clinical study aiming at therapeutic equivalence (10) . In this regard, it is hard to conceive that two biological products showing similarity across a comprehensive non-clinical and clinical data-package will behave dissimilarly in an insensitive therapeutic clinical study aiming to show therapeutic equivalence. This line of thinking is the cornerstone behind the revision of the BS regulatory background that is taking place worldwide and that has lead to an in depth revision of the EU regulatory recommendations (2-7). The key idea underlining the assessment of biosimilarity is based on the evaluation of the totality of data, non-clinical and clinical, guarantying an acceptable level of similarity between BS and RP. Indeed, and since validated biomarker may not be available for some clinical conditions, EU requirements establish as a rule that at least one clinical study aiming to show equivalence between the BS and the RP should be conducted. Changing the regulatory requirements by demanding further therapeutic equivalence in all indications is considered today at best inefficient and at worst ethically questionable.
Questioning the marketing authorization conditions of an approved drug based on non-scientifically driven concerns is not considered the right strategy to protect patients, but rather a way to introduce alarm and confusion. BSs can be prescribed by the physicians with full confidence in all the approved indications and according to their labeling.
We would like to emphasize however, in line with the authors of the Position Statement, that BSs are entirely different from chemical generics. BS medicinal products are obliged to develop a full pharmacovigilance and risk management programs in order to ensure a proper safety signal detection system for each of them individually considered. These measures require full traceability and are not compatible with substitution policies without medical supervision. This must be our primary concern as physicians responsible for the consequences of our therapeutic decisions.
